Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis

Inflammation Research

Volumn 63, Issue 2, 2014, Pages 161-169

  Verma, Nirmal ^a   Verma, Ravi ^a   Kumari, Reena ^a   Ranjha, Raju ^a   Paul, Jaishree ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Dextran sodium salt; Disease activity index; Gut microbiota; Myeloperoxidase; Salicin

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIA; BACTERIAL LOAD; BENZYL ALCOHOLS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; FECES; GLUCOSIDES; INTESTINES; MALE; MICE; MICROBIOTA; PEROXIDASE; RNA, BACTERIAL; RNA, MESSENGER; RNA, RIBOSOMAL, 16S;

EID: 84895074111     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-013-0685-1     Document Type: Article

References (38)

1. Fiocchi C. Inflammatory bowel disease: aetiology and pathogenesis. Gastroenterology. 1998;115:182-205. (Pubitemid 28307304)
2. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol. 1997;92:5S-11S.
3. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1998;98:694-702.
4. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238-49.
5. Hedner T, Everts B. The early clinical history of salicylates in rheumatology and pain. Clin Rheumatol. 1998;17:17-25. (Pubitemid 28198095)
6. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29. (Pubitemid 34851835)
7. Basset C, Holton J. Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog. 2002;85:33-56.
8. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest. 2004;113:1296-306. (Pubitemid 39069929)
9. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol. 2001;234:29-40. (Pubitemid 33070909)
10. Seksik P, Sokol H, Lepage P, et al. The role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:11-8. (Pubitemid 44326413)
11. Farrell RJ, Lamont JT. Microbial factor in inflammatory bowel disease. Gastroentrol Clin North Am. 2002;3:41-62. (Pubitemid 34733032)
12. Oscar CTC, Jose M, Angel G. Aetiology of inflammatory bowel disease: role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr. 2005;24:339-52. (Pubitemid 40668419)
13. Delaney BC, Moayyedi P. Dyspepsia. Health care needs assessment, 3rd series. Department of Health, Radcliffe Medical Press, http://hcna.radcliffe- oxford.com/dysframe.htm (2003).
14. Ghosh S, Van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut. 2004;53:620-2. (Pubitemid 38561434)
15. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549. (Pubitemid 34293433)
16. Pizarro TT, Arseneau KO, Bamias G, Cominelli F. Mouse models for the study of Crohn's disease. Trends Mol Med. 2003;9:218-22. (Pubitemid 36713392)
17. Talley NJ, Stanghellini V, Heading RC, et al. Functional gastrointestinal disorders. Gut. 1999;45:37-42.
18. Maxton DG, Morris J, Whorwell PJ. More accurate diagnosis of irritable bowel syndrome by the use of "non-colonic" symptomatology. Gut. 1991;32:784-6.
19. Verma R, Verma AK, Ahuja V, Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol. 2010;48:4279-82.
20. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology. 2006;130:1707-20. (Pubitemid 43668852)
21. Rand TG, Sun M, Gilyan A, Downey J, Miller JD. Dectin-1 and inflammation-associated gene transcription and expression in mouse lungs by a toxic (1,3)-beta-d glucan. Arch Toxicol. 2010;84(3):205-20.
22. Asakura H. Ulcerative colitis and intestinal bleeding. Nippon Rinsho. 1998;56:2354-9.
23. Lee S, Lim KT. Glycoprotein isolated from Ulmus davidiana Nakai regulates expression of iNOS and COX-2 in vivo and in vitro. Food Chem Toxicol. 2007;45:990-1000. (Pubitemid 46507690)
24. Malle E, Furtmuller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol. 2007;152:838-54. (Pubitemid 350100486)
25. Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V, Alarcón de la Lastra C. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 2007;7:333-42. (Pubitemid 46186172)
26. Monteleone I, Vavassori P, Biancone L, Monteleone G. Pallone F immunoregulation in the gut: success and failures in human disease. Gut. 2002;50:III60-4. (Pubitemid 34407458)
27. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-9. (Pubitemid 23353163)
28. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-66. (Pubitemid 24163114)
29. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol. 1997;159:6276-82. (Pubitemid 127471570)
30. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22-8. (Pubitemid 29013489)
31. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-34. (Pubitemid 29203012)
32. Rojas-Cartagena C, Flores I, Appleyard CB. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine. 2005;32:85-93. (Pubitemid 41563038)
33. Kinoshita K, Hori M, Fujisawa M, Sato K, Ohama T, Momotani E, et al. Role of TNF-alpha in muscularis inflammation and motility disorder in a TNBS-induced colitis model: clues from TNF-alpha-deficient mice. Neurogastroenterol Motil. 2006;18:578-88. (Pubitemid 43855811)
34. Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol. 2004;25:9-14.
35. Talero E, Sánchez-Fidalgo S, Ramón Calvo J, Motilva V. Galanin in the trinitrobenzene sulfonic acid rat model of experimental colitis. Int Immunopharmacol. 2006;6:1404-12. (Pubitemid 44038681)
36. Dong L, Li J, Liu Y, Yue W, Luo X. Toll-like receptor 2 monoclonal antibody or/and Toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteriain dextran sulfate sodium-induced colitis in mice. J Gastroenterol Hepatol. 2012;27:110-9.
37. Sydora BC, Albert EJ, Foshaug RR, Doyle JSG, Churchill TA, Fedorak RN. Intravenous injection of endogenous microbial components abrogates DSS-induced colitis. Dig Dis Sci. 2012;57:345-54.
38. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet. 2003;36:512-9. (Pubitemid 36173720)